Transcranial Magnetic Stimulation for Stroke Recovery
Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique that uses electromagnetic induction to generate electrical currents in targeted brain regions. Over the past two decades, repetitive TMS (rTMS) has emerged as a promising adjunctive therapy for stroke rehabilitation, with the strongest evidence supporting its use for upper limb motor recovery and post-stroke aphasia. Unlike implanted vagus nerve stimulation, rTMS is not FDA-approved specifically for stroke rehabilitation, but it has received "Level A" evidence rating for motor recovery in clinical guidelines.
🔹 Bottom Line: TMS for Stroke Recovery
- Evidence level: "Level A" (highest) for upper limb motor recovery per 2020 international guidelines; strong meta-analytic support for post-stroke aphasia.
- Mechanism: Rebalances interhemispheric inhibition — excitatory stimulation to ipsilesional cortex or inhibitory stimulation to contralesional cortex.
- Protocols: High-frequency rTMS (≥5 Hz) or iTBS to ipsilesional M1; low-frequency rTMS (1 Hz) or cTBS to contralesional M1.
- Theta burst stimulation (TBS): Achieves similar effects in ~3 minutes vs 20–30 minutes for conventional rTMS.
- Best used as adjunct: Combined with physical/occupational therapy or speech-language therapy — not as standalone treatment.
- FDA status: Not FDA-approved for stroke rehabilitation; FDA-cleared for treatment-resistant depression.
Mechanism of Action
The therapeutic rationale for TMS in stroke recovery is based on the interhemispheric inhibition model. After unilateral stroke, the balance between hemispheres is disrupted: the contralesional (unaffected) hemisphere becomes relatively overactive and exerts excessive inhibition on the damaged ipsilesional hemisphere through transcallosal pathways. This maladaptive plasticity may impede recovery.
TMS can rebalance hemispheric activity through two complementary strategies:
- Excitatory stimulation (high-frequency rTMS or iTBS) applied to the ipsilesional primary motor cortex (M1) → increases cortical excitability and motor output from the affected hemisphere
- Inhibitory stimulation (low-frequency rTMS or cTBS) applied to the contralesional M1 → reduces excessive inhibition from the unaffected hemisphere
Both approaches aim to enhance neuroplasticity and promote functional reorganization in motor and language networks. The effects are mediated through long-term potentiation (LTP) and long-term depression (LTD)-like mechanisms at the synaptic level.
Types of TMS Protocols
| Protocol | Frequency | Target | Effect | Duration | Pulses |
|---|---|---|---|---|---|
| HF-rTMS | 5–20 Hz | Ipsilesional M1 | Excitatory | 20–30 min | 1,000–2,000 |
| LF-rTMS | 1 Hz | Contralesional M1 | Inhibitory | 20–30 min | 1,200–1,800 |
| iTBS | 50 Hz bursts at 5 Hz | Ipsilesional M1 | Excitatory | ~3 min | 600 |
| cTBS | 50 Hz continuous bursts | Contralesional M1 | Inhibitory | ~40 sec | 600 |
🔹 Clinical Relevance: Why Theta Burst Stimulation?
- Time efficiency: iTBS delivers 600 pulses in ~3 minutes vs 20–30 minutes for conventional rTMS
- Similar efficacy: Meta-analyses show comparable motor improvements to conventional protocols
- Patient comfort: Shorter sessions improve tolerability and compliance
- Cost-effectiveness: More patients can be treated per day
- Ongoing trials: B-STARS2 (phase 3, 454 patients) is evaluating cTBS as standard of care
Applications in Stroke Recovery
Upper Limb Motor Recovery
Motor recovery has the strongest evidence base for TMS in stroke rehabilitation. Multiple meta-analyses demonstrate significant improvements in upper limb function with both conventional rTMS and theta burst protocols.
Key evidence:
- B-STARS trial (2023): 60 patients randomized to cTBS vs sham within 3 weeks of stroke. cTBS significantly improved Action Research Arm Test (ARAT) scores at 3 months (+12.8 points vs +5.0 points) with benefits sustained at 12 months.
- High-dose TBS trial (2024): Neuroimaging-guided iTBS and cTBS both outperformed sham on FMA-UE at 3 weeks (p<0.01). cTBS showed particular benefit in chronic stroke patients.
- Meta-analysis (2024): 382 participants across 10 studies showed significant FMA-UE improvements with rTMS (SMD 1.28, 95% CI 1.08–1.48).
- Systematic review (2025): rTMS improves post-stroke motor outcomes across multiple domains, with strongest effects in acute/subacute phase.
🔹 Clinical Relevance: Timing Matters
- Subacute phase (1–12 weeks): Greatest potential for benefit; enhanced neuroplasticity window
- Chronic phase (>3 months): Still beneficial but effect sizes may be smaller
- Acute phase (<1 week): Limited data; safety concerns about early intervention
- MEP status: Patients with preserved motor evoked potentials may respond better, though MEP-negative patients can still benefit
Post-Stroke Aphasia
rTMS has emerged as a valuable adjunct to speech-language therapy (SLT) for post-stroke aphasia, particularly non-fluent aphasia. The primary approach uses inhibitory 1 Hz rTMS over the right pars triangularis (Broca's area homolog) to reduce compensatory right hemisphere recruitment.
Key evidence:
- Meta-analysis (2024, 47 RCTs, 2,190 patients): rTMS significantly improved naming, repetition, spontaneous speech, and auditory comprehension in non-fluent aphasia. Also reduced post-stroke depression symptoms.
- NORTHSTAR-CA trial: Compared rTMS + SLT vs sham + SLT in subacute and chronic aphasia. Significant naming improvement with rTMS in subacute patients only (median 1.91 vs 1.02 Z-score improvement, p=0.046). Chronic patients showed no additional benefit over SLT alone.
- M-MAT combination trial (2025): 1 Hz rTMS + 35 hours of multimodality aphasia therapy over 10 days was safe and feasible in chronic aphasia, though results were comparable to sham + therapy.
🔴 Important: Aphasia TMS Considerations
- rTMS appears most beneficial in subacute phase (5–45 days post-stroke) for aphasia
- Chronic aphasia patients may benefit more from intensive SLT alone
- Always combine with speech-language therapy — rTMS is an adjunct, not standalone
- Lesion location may affect response; personalized targeting may be needed
Post-Stroke Depression
High-frequency rTMS (10–20 Hz) applied to the left dorsolateral prefrontal cortex (DLPFC) has established efficacy for major depression and can be considered for post-stroke depression. The 2026 AHA/ASA acute stroke guidelines reference rTMS as a potential adjunctive therapy for post-stroke depression based on systematic review evidence.
Lower Limb and Balance
Evidence for lower limb recovery is less robust than for upper limb. Recent meta-analyses suggest:
- Cerebellar iTBS: May improve Berg Balance Scale scores more effectively than M1 stimulation for lower limbs
- iTBS to lower limb M1: Shows trends toward improvement in FMA-LE and walking performance but less consistent than upper limb data
Patient Selection
| Factor | Consideration | Evidence |
|---|---|---|
| Timing post-stroke | Subacute (1–12 weeks) may have greatest benefit | Multiple trials show larger effects in earlier phases |
| Stroke type | Both ischemic and hemorrhagic | B-STARS included both; similar responses |
| MEP status | Preserved MEPs may predict better response | Some trials show greater benefit in MEP+ patients |
| Lesion location | Subcortical lesions may respond better than large cortical | Cortical M1 damage may limit ipsilesional stimulation efficacy |
| Severity | Moderate impairment (some residual function) | Complete paralysis shows less response |
| Cognition | Ability to participate in paired rehabilitation | TMS alone without therapy is less effective |
Practical Protocol Considerations
🔹 Practical Workflow: rTMS for Motor Recovery
Step 1: Patient Evaluation
- Screen for contraindications (see below)
- Baseline motor assessment (FMA-UE, ARAT, grip strength)
- Determine MEP status if available
Step 2: Motor Threshold Determination
- Resting motor threshold (RMT) measured from contralesional M1
- If no MEP from ipsilesional side, use mirror location at 100% contralesional RMT
- Stimulation typically delivered at 80–120% RMT
Step 3: Target Localization
- Anatomical landmarks (5 cm anterior to vertex) or
- Neuronavigation with MRI for precise targeting
- Hotspot determination for optimal MEP response
Step 4: Treatment Sessions
- Typically 10–20 sessions over 2–4 weeks
- Daily sessions (5 days/week) most common
- Immediately followed by rehabilitation therapy (OT/PT)
Step 5: Reassessment
- Post-treatment motor assessment
- Follow-up at 1–3 months to assess durability
Safety and Contraindications
🔴 Absolute Contraindications
- Implanted metallic hardware in or near the head (excluding titanium)
- Cochlear implants
- Deep brain stimulators or other implanted neurostimulators
- Implanted medication pumps
| Relative Contraindications | Consideration |
|---|---|
| History of seizures/epilepsy | Increased seizure risk; may still be used with caution |
| Skull defects/craniectomy | Altered current distribution; avoid stimulating near defect |
| Pregnancy | Limited safety data; generally avoided |
| Severe cardiovascular disease | Rare vagal effects reported |
| Medications lowering seizure threshold | TCAs, antipsychotics, stimulants — assess risk/benefit |
Common side effects:
- Headache: Most common (5–20%); usually mild and transient
- Scalp discomfort: At stimulation site; improves with sessions
- Transient hearing changes: Use of earplugs recommended
- Seizure: Very rare (<0.1%); slightly higher with high-frequency protocols
Comparison: TMS vs Other Neuromodulation for Stroke
| Modality | Mechanism | Invasiveness | FDA Status (Stroke) | Evidence Level |
|---|---|---|---|---|
| rTMS/TBS | Electromagnetic induction | Non-invasive | Not approved | Level A (motor) |
| tDCS | Direct current polarization | Non-invasive | Not approved | Level B |
| Implanted VNS | Vagal neuromodulation | Surgical implant | FDA approved (Vivistim) | Level A |
| ta-VNS | Transcutaneous vagal | Non-invasive | Investigational | Emerging |
| Cerebellar DBS | Deep brain stimulation | Highly invasive | Investigational | Early phase |
| Spinal cord stimulation | Epidural stimulation | Invasive | Investigational | Early phase |
🔹 TMS vs VNS: How to Choose?
- TMS: Non-invasive, no surgery required, widely available, requires frequent clinic visits (10–20 sessions), no home use
- VNS: Requires surgical implantation, FDA-approved, enables home-based ongoing therapy, higher upfront cost, durable long-term effects
- Consider TMS if: Patient prefers non-invasive approach, subacute phase, facility has TMS capability, trial of neuromodulation before committing to implant
- Consider VNS if: Chronic stroke (≥9 months), moderate impairment (FMA-UE 20–40), willing to undergo surgery, wants home-based long-term therapy
Limitations and Knowledge Gaps
- Protocol heterogeneity: Optimal frequency, intensity, duration, and target not standardized
- Individual variability: Significant inter-individual differences in response; biomarkers to predict responders needed
- Limited long-term data: Most trials report outcomes at 3 months; durability beyond 1 year unclear
- No FDA approval for stroke: Unlike VNS, rTMS remains off-label for stroke rehabilitation
- Access and cost: Requires specialized equipment and trained personnel; not universally available
- Combination protocols: Optimal pairing with specific rehabilitation therapies not established
Key Trials Summary
| Trial/Study | Year | Protocol | Population | N | Key Finding |
|---|---|---|---|---|---|
| B-STARS | 2023 | cTBS contralesional M1 | Subacute stroke (<3 wks) | 60 | ARAT +12.8 vs +5.0 at 3 mo (p<0.05) |
| High-dose TBS | 2024 | iTBS/cTBS neuroimaging-guided | Subacute/chronic | 60 | Both iTBS and cTBS superior to sham |
| Kim et al. | 2020 | 1 Hz LF-rTMS contralesional | Subacute ischemic | 54 | FMA-UE improved; effects at 3 mo |
| rTMS + fMRI | 2018 | HF vs LF vs sham | Early stroke (<2 wks) | 60 | Both HF and LF improved FMA-UE vs sham |
| Aphasia meta-analysis | 2024 | Various rTMS protocols | Non-fluent aphasia | 2,190 | Improved naming, repetition, spontaneous speech |
| NORTHSTAR-CA | 2022 | 1 Hz rTMS + SLT | Subacute vs chronic aphasia | 67 | Benefit in subacute only; not chronic |
| iTBS balance | 2024 | Cerebellar iTBS | Stroke with imbalance | 290 | BBS improved; cerebellar > M1 target |
| B-STARS2 (ongoing) | 2024– | cTBS phase 3 | Subacute stroke | 454 | Primary endpoint: FMA-UE at 90 days |
Conclusion
Transcranial magnetic stimulation represents a promising non-invasive neuromodulation approach for stroke rehabilitation, with the strongest evidence supporting its use for upper limb motor recovery and post-stroke aphasia. Both conventional rTMS and the more time-efficient theta burst protocols can enhance outcomes when combined with rehabilitation therapy. While not yet FDA-approved specifically for stroke, rTMS has achieved "Level A" evidence for motor recovery and is increasingly integrated into comprehensive stroke rehabilitation programs. The ongoing B-STARS2 phase 3 trial will provide pivotal data on whether cTBS should become standard of care. For now, TMS offers a valuable non-invasive option for patients seeking to augment their recovery, particularly in the critical subacute window when neuroplasticity is greatest.
References
- Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol. 2020;131:474–528.
- Vink JJT, et al."; Continuous theta-burst stimulation of the contralesional primary motor cortex for promotion of upper limb recovery after stroke: a randomized controlled trial. Stroke. 2023;54:xxx–xxx.
- Cheng J, et al. Repetitive transcranial magnetic stimulation for post-stroke non-fluent aphasia: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2024;15:1348695.
- Zumbansen A, et al. Differential effects of speech and language therapy and rTMS in chronic versus subacute post-stroke aphasia: results of the NORTHSTAR-CA trial. Neurorehabil Neural Repair. 2022;36(4):291–302.
- Lin F, Hamilton RH, Sloane KL. Repetitive transcranial magnetic stimulation for post-stroke rehabilitation: a systematic review and meta-analysis. medRxiv. 2025.
- Chen K, et al. Effect of theta burst stimulation on lower extremity motor function improvement and balance recovery in patients with stroke. Medicine. 2024;103(44):e40098.
- Vink JJT, et al. B-STARS2: Early contralesional continuous theta burst stimulation (cTBS) to promote upper limb recovery after stroke – rationale and design of a phase-3 multicentre trial. Int J Stroke. 2025.
- Prabhakaran S, et al. 2026 Guideline for the early management of patients with acute ischemic stroke. Stroke. 2026;57:xxx–xxx.